Location:
Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus, UNSW Sydney
Contact for enquiries
Rata Joseph, +61 (2) 9385 0900 or recpt@kirby.unsw.edu.au
Kirby Institute Seminar Series presents
 |
Senior Clinical Project Coordinator, Therapeutic and Vaccine Research Program, Kirby Institute Sally Hough is Senior Project Coordinator at TVRP at the Kirby Institute with over 13 years experience project managing clinical trials with academic and pharmaceutical industry partners. She joined the Kirby Institute in 2010 and since this time has worked on trials relating to optimising ART implementation and interventions for co-morbidities for people living with HIV including cardiovascular disease and cancer. Prior to joining the Kirby, Sally worked at The George Institute for International Health, project managing large scale international cardiovascular clinical trials related to diabetes, heart failure and polypill strategies. |
|
 |
||
 |
Research Associate, Immunovirology and Pathogenesis Program, Kirby Institute David van Bockel is a research associate of the Kirby Institute with a specific footing in applied basic research based within the Immunovirology and Pathogenesis program, since 2012. Prior to this he had a varied basic and applied medical research career with post-doctoral placements at Barts and the London School of Medicine and Dentistry, UNSW Sydney and Sydney University Faculty of Medicine; investigating pathogenesis of infectious diseases and autosomal disorders. Principal projects include correlative immunological research work that mainly include HIV, HPV and tuberculosis. Current clinical projects include trials to evaluate the natural history of, and small-molecule therapies to treat, HPV-driven disease. |
Abstract
Despite the impact of cART on improvements in health outcomes for people living with HIV, elevated levels of biomarkers of coagulation, inflammation and immune activation in people with HIV remain and are associated with an excess of morbidity and mortality. The ADVICE study aimed to reduce HIV associated hypercoagulation and inflammation using vorapaxar, a novel PAR-1 inhibitor.